Bubs share price tumbles 5% amid broker downgrade

Bubs shares are heading south on Tuesday…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Bubs shares are giving back some of Monday's impressive gains
  • Its shares rocketed higher on news of a deal with the US Government for 1.25 million tins of infant formula
  • A leading broker has downgraded Bubs shares today largely on valuation grounds after the strong gain

The Bubs Australia Ltd (ASX: BUB) share price has run out of steam on Tuesday morning.

At the time of writing, the infant formula company's shares are down 5% to 64.5 cents.

person holding hand to head in despair while holding a glass of milk with the other hand.

Image source: Getty Images

Why is the Bubs share price sinking today?

There appear to be a couple of catalysts for the weakness in the Bubs share price on Tuesday.

The first is profit taking after a stellar gain on Monday following news that the company has struck a deal with the Biden Administration to supply 1.25 million tins of infant formula to help with shortages in the United States.

The market's reaction was so positive that the Bubs share price remains up 33% this week despite today's decline.

What else is weighing on its shares?

Also potentially weighing on the Bubs share price is a broker note out of Bell Potter this morning.

According to the note, the broker has downgraded the company's shares to a (speculative) hold rating with an improved price target of 75 cents.

Bell Potter was pleased with the aforementioned news but highlights that the US FDA's infant formula enforcement discretion policy (IFEDP) is only in place effect until November. As such, it is treating this development largely as a temporary sales boost. It said:

The IFEDP is only in effect until Nov'22 and in this light we have treated this largely as a temporary sales boost, with additional toddler formula sales thereafter.

Though, the broker does acknowledge that the announcement should boost brand awareness in the US, which is a market it believes could be very lucrative for Bubs. It explained:

At the very least the announcement de-risks near term sales forecasts for BUB, which are premised on execution against the Alpha Group equity linked distribution deal announced earlier in the year.

It could also be a viewed as a positive signal for BUB's achieving future USFDA approval for its infant products and enhanced brand awareness for its existing toddler products which are already distributed in the US. The upside potential in the US is high, particularly the organic grass fed IMF product, where we have estimated in the past a 2.0-4.5m pa tin opportunity for similar products.

However, due to the strong rise in the Bubs share price, the broker doesn't believe the risk/reward on offer is enough to maintain a buy rating.

It concludes:

This is a good announcement for BUB and at the least will likely result in increased US brand awareness while benefiting near term cashflows. BUB remains a high ceiling growth play in the IMF, however, in light of the recent share price gain we downgrade our rating from Buy, Speculative risk to Hold, Speculative risk.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BUBS AUST FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A woman stands in a field and raises her arms to welcome a golden sunset.
Gold

4 ASX 200 gold shares to buy: Experts

Experts explain their buy ratings following these miners' June quarter reports.

Read more »

Three balls at various places on a cycle.
Broker Notes

6 ASX uranium shares to buy ahead of yellow cake rising to US$200 per pound: experts

This broker tips 83% to 295% upside over 12 months for its 6 top ASX uranium share picks.

Read more »

A hipster-looking man with bushy beard and multiple arm tattoos sits on the floor against a sofa reading a tablet with his hand on his chin as though he is deep in thought.
Broker Notes

Buy, hold, sell: Capstone Copper, Lindsay Australia, Woodside shares

Let's take a look at three fresh buy, hold, and sell calls from the experts. 

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Broker Notes

Down 23% and 58%, should I buy TechnologyOne and Xero shares now?

A leading expert provides his forecasts for TechnologyOne and Xero shares.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands.
Broker Notes

Buy, hold, sell: Ramsay Healthcare, Xero, Electro Optic Systems shares

Let's take a look at three fresh buy, hold, and sell calls from the experts. 

Read more »

ASX 300 share investors in suits running a race on an athletics track
Broker Notes

Why Macquarie shares are forecast to outpace ASX bank stocks like CBA and Westpac

A leading analyst expects Macquarie shares to keep outpacing the big four ASX banks, including CBA and Westpac.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Broker Notes

Down 27%, are Boss Energy shares a buy, hold or sell?

A leading analyst delivers his outlook for Boss Energy’s beaten-down shares.

Read more »

a woman holds a cup to her ear and leans in with a wide mouthed expression on her face as though she is listening to interesting and perhaps surprising information.
Broker Notes

Buy, hold, sell: Dexus, Origin Energy, Magellan shares

Let's start the week with some fresh ratings from Dylan Evans of Catapult Wealth.

Read more »